# Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa

Page: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-68-ash-2025-myeloma-special-majestec-3-and-the-bispecific-revolution-with-dr-luciano-costa
Text version: https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-68-ash-2025-myeloma-special-majestec-3-and-the-bispecific-revolution-with-dr-luciano-costa.md
Podcast: [Blood Cancer Talks](https://stenobird.com/podcast/blood-cancer-talks-5570002)
Published: 2026-01-02T11:50:15+00:00
Episode link: https://share.transistor.fm/s/7f2b38c0
Audio file: https://media.transistor.fm/7f2b38c0/20a33283.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-68-ash-2025-myeloma-special-majestec-3-and-the-bispecific-revolution-with-dr-luciano-costa
Duration seconds: 2750

## Resource

Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the future implications for treatment. The episode also examines the comparative efficacy of bispecific T-cell engagers versus CAR-T therapies, along with spirited discussion on the potential for fixed-duration treatment in myeloma care. Episode Highlights Main Topics Covered MajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care Trial design and patient population Primary endpoint: Progression-free survival (PFS) MRD negativity rates and depth of response Overall survival and safety profile Clinical implications for treatment selection Treatment Selection in Early Relapse Comparing MajesTEC-3 and CARTITUDE-4 patient populations Framework for choosing between bispecific antibodies vs. CAR T-cell therapy Managing anti-CD38 exposed patients Link to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-68-ash-2025-myeloma-special-majestec-3-and-the-bispecific-revolution-with-dr-luciano-costa/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-68-ash-2025-myeloma-special-majestec-3-and-the-bispecific-revolution-with-dr-luciano-costa.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.